Sanofi Q1 Sales Jump 14% to €10.51B, FDA Clears Tzield for One-Year-Olds
Sanofi’s Q1 profit and revenue topped market expectations, driven by resilient Dupixent demand, and group sales rose 14% to €10.51B at constant currency from new launches and acquisitions. The FDA expanded Tzield approval to delay stage 3 type 1 diabetes onset in patients as young as one year old.
1. Q1 Profit and Revenue Beat Estimates
Sanofi reported first-quarter profit and revenue exceeding market forecasts, led by resilient demand for its blockbuster Dupixent therapy. This performance precedes a planned leadership transition later this year.
2. Constant-Currency Sales Up 14% to €10.51B
Group sales rose 14% to €10.51 billion on a constant-currency basis, fueled by new product launches and recent acquisitions that broadened the portfolio. Growth was broad-based across major markets, reflecting robust uptake of innovative treatments.
3. FDA Expands Tzield Approval to Youngest Patients
The FDA expanded approval of teplizumab-mzwv, marketed as Tzield, to delay stage 3 type 1 diabetes onset in patients as young as one-year-old with stage 2 disease. The decision follows one-year safety and pharmacokinetic data from the PETITE-T1D Phase IV trial and builds on existing approvals across multiple regions.